Clinical study investigating the tolerability of SPI 256 in patients with HIV infections.
Latest Information Update: 23 Dec 2008
At a glance
- Drugs SPI 256 (Primary) ; Ritonavir
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Sequoia Pharmaceuticals
- 23 Dec 2008 Profile checked.
- 12 Dec 2007 New trial record.